deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02204085

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: Beth Israel Deaconess Medical Center

Conditions Acute Myeloid Leukemia, in Relapse Recurrent Adult Acute Myeloid Leukemia
Interventions GO-203-2c GO-203-2c + Decitabine
Updated 16 times since 2017 Last updated: Jan 23, 2025 Started: Sep 30, 2014 Primary completion: Sep 30, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Acute Myeloid Leukemia, in Relapse and Recurrent Adult Acute Myeloid Leukemia and is currently ongoing. Beth Israel Deaconess Medical Center leads this study, which shows 16 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~May 2019 · 8 months · monthly snapshot~May 2019 – ~Jan 2020 · 8 months · monthly snapshot~Jan 2020 – ~Dec 2020 · 11 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – present · 17 months · monthly snapshot

Change History

16 versions recorded

  1. Feb 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Feb 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Feb 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jan 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. May 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Sep 2018 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute
Data source: Beth Israel Deaconess Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations